BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26899600)

  • 21. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
    Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
    Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
    Grossmann V; Tiacci E; Holmes AB; Kohlmann A; Martelli MP; Kern W; Spanhol-Rosseto A; Klein HU; Dugas M; Schindela S; Trifonov V; Schnittger S; Haferlach C; Bassan R; Wells VA; Spinelli O; Chan J; Rossi R; Baldoni S; De Carolis L; Goetze K; Serve H; Peceny R; Kreuzer KA; Oruzio D; Specchia G; Di Raimondo F; Fabbiano F; Sborgia M; Liso A; Farinelli L; Rambaldi A; Pasqualucci L; Rabadan R; Haferlach T; Falini B
    Blood; 2011 Dec; 118(23):6153-63. PubMed ID: 22012066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
    Liu Y; Cao Y; Lin Y; Dong WM; Lin RR; Gu Q; Xie XB; Gu WY
    Transplant Proc; 2018 Apr; 50(3):959-963. PubMed ID: 29661468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response and progression on midostaurin in advanced systemic mastocytosis:
    Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
    Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomics in acute myeloid leukemia: from identification to personalization.
    Martin JM; Winer ES
    R I Med J (2013); 2015 Nov; 98(11):27-30. PubMed ID: 26517252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
    Mechaal A; Menif S; Abbes S; Safra I
    Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Hu RP
    Hematology; 2014 Sep; 19(6):324-8. PubMed ID: 24164801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
    Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
    Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
    Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
    [No Abstract]   [Full Text] [Related]  

  • 31. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.
    Dicker F; Haferlach C; Sundermann J; Wendland N; Weiss T; Kern W; Haferlach T; Schnittger S
    Leukemia; 2010 Aug; 24(8):1528-32. PubMed ID: 20520634
    [No Abstract]   [Full Text] [Related]  

  • 32. TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.
    Tian X; Xu Y; Yin J; Tian H; Chen S; Wu D; Sun A
    Int J Hematol; 2014 Jul; 100(1):96-104. PubMed ID: 24859829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rethinking the gold standard for recurrent DNA mutations detection in acute myeloid leukemia.
    Novaretti MC
    Eur J Haematol; 2016 Feb; 96(2):109-10. PubMed ID: 26110968
    [No Abstract]   [Full Text] [Related]  

  • 34. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.
    Ånensen N; Hjelle SM; Van Belle W; Haaland I; Silden E; Bourdon JC; Hovland R; Taskén K; Knappskog S; Lønning PE; Bruserud Ø; Gjertsen BT
    Oncogene; 2012 Mar; 31(12):1533-45. PubMed ID: 21860418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.
    Alpermann T; Schnittger S; Eder C; Dicker F; Meggendorfer M; Kern W; Schmid C; Aul C; Staib P; Wendtner CM; Schmitz N; Haferlach C; Haferlach T
    Haematologica; 2016 Feb; 101(2):e55-8. PubMed ID: 26471486
    [No Abstract]   [Full Text] [Related]  

  • 37. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
    Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
    Kövy P; Őrfi Z; Bors A; Kozma A; Gopcsa L; Dolgos J; Lovas N; Harasztdombi J; Lakatos V; Király Á; Mikala G; Vályi-Nagy I; Reményi P; Andrikovics H
    PLoS One; 2021; 16(6):e0253386. PubMed ID: 34153064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.
    Wakita S; Yamaguchi H; Omori I; Terada K; Ueda T; Manabe E; Kurosawa S; Iida S; Ibaraki T; Sato Y; Todoroki T; Hirakawa T; Ryotokuji T; Arai K; Kitano T; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2013 Apr; 27(5):1044-52. PubMed ID: 23135354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.
    Alseraye FM; Zuo Z; Bueso-Ramos C; Wang S; Medeiros LJ; Lu G
    Int J Clin Exp Pathol; 2011 Apr; 4(4):371-7. PubMed ID: 21577323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.